|
|
||||||||
AFIP ARCHIVES |
1 From the Department of Diagnostic Imaging, Brown Medical School, Rhode Island Hospital, 593 Eddy St, Providence, RI 02903 (G.F.A.); Department of Radiology and Nuclear Medicine, Uniformed Services University of the Health Sciences, Bethesda, Md (M.L.R.); Department of Diagnostic Radiology, University of Maryland Medical System, Baltimore (A.A.F., J.R.G.); and Departments of Pulmonary and Mediastinal Pathology (T.J.F.) and Radiologic Pathology (A.A.F., J.R.G.), Armed Forces Institute of Pathology, Washington, DC. Received January 9, 2004; revision requested January 23 and received February 10; accepted February 16. All authors have no financial relationships to disclose. Address correspondence to G.F.A. (e-mail: gabbott@cox.net).
Pulmonary Langerhans cell histiocytosis (PLCH) is an isolated form of Langerhans cell histiocytosis that primarily affects cigarette smokers. PLCH is characterized by peribronchiolar proliferation of Langerhans cell infiltrates that form stellate nodules. The nodular lesions frequently cavitate and form thick- and thin-walled cysts, which are thought to represent enlarged airway lumina. PLCH lesions display temporal microscopic heterogeneity, with progression from dense cellular nodules to apparently cavitary nodules to increasing degrees of fibrosis that may extend along alveolar walls. In advanced cases, fibrotic scars are surrounded by enlarged, distorted air spaces. Affected patients are typically young adults who often present with cough and dyspnea. The characteristic radiographic features of PLCH are bilateral nodular and reticulonodular areas of opacity that predominantly involve the upper and middle lung zones with relative sparing of the lung bases. High-resolution computed tomography (CT) shows nodules and cysts in the same distribution and allows a confident prospective diagnosis of PLCH in the appropriate clinical setting. In typical cases, a predominantly nodular pattern is seen on CT scans in early phases of the disease, whereas a cystic pattern predominates in later phases. The radiologic abnormalities may regress, resolve completely, become stable, or progress to advanced cystic changes. Treatment consists of smoking cessation, but corticosteroid therapy may be useful in selected patients. Chemotherapeutic agents and lung transplantation may be offered to patients with advanced disease. The prognosis of PLCH is variable with frequent regression, stabilization, or recurrence of disease that does not correlate with cessation or continuation of smoking.
Index Terms: Histiocytosis, 60.66 Lung, CT, 60.12118 Lung, diseases, 60.66
This article has been cited by other articles:
![]() |
S. Schmidt, G. Eich, A. Geoffray, S. Hanquinet, P. Waibel, R. Wolf, I. Letovanec, L. Alamo-Maestre, and F. Gudinchet Extraosseous Langerhans Cell Histiocytosis in Children RadioGraphics, May 1, 2008; 28(3): 707 - 726. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Green and J. N. Allen Cough, Dyspnea, and Reticulonodular Opacities in a 58-Year-Old Smoker Chest, August 1, 2007; 132(2): 700 - 703. [Full Text] [PDF] |
||||
![]() |
D. L. Leatherwood, D. E. Heitkamp, and R. E. Emerson Best Cases from the AFIP: Pulmonary Langerhans Cell Histiocytosis RadioGraphics, January 1, 2007; 27(1): 265 - 268. [Full Text] [PDF] |
||||
![]() |
M. Colombat, M. Stern, O. Groussard, D. Droz, M. Brauner, D. Valeyre, H. Mal, C. Taille, I. Monnet, M. Fournier, et al. Pulmonary Cystic Disorder Related to Light Chain Deposition Disease Am. J. Respir. Crit. Care Med., April 1, 2006; 173(7): 777 - 780. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. F. Abbott, M. L. Rosado-de-Christenson, A. A. Frazier, T. J. Franks, R. D. Pugatch, and J. R. Galvin From the Archives of the AFIP: Lymphangioleiomyomatosis: Radiologic-Pathologic Correlation RadioGraphics, May 1, 2005; 25(3): 803 - 828. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| RADIOGRAPHICS | RADIOLOGY | RSNA JOURNALS ONLINE |